Selected Abstracts

Phase I Clinical Trial Demonstrates Safety and Efficacy of Intrathecal Autologous Mesenchymal Stem Cell-Derived Neural Progenitors (MSC-NPs) for the Treatment of Progressive Multiple Sclerosis

Violaine Harris, James Stark, Gloria Joo, Tamara Vyshkina, and Saud A. Sadiq, MD Presented at the American Academy of Neurology (AAN) 2017 Annual Meeting, held April 22-28, 2017 in Boston, Massachusetts.

Intrathecal treatment using autologous mesenchymal stem cell neural progenitors (MSC-NP) may improve established disability in MS: results of a phase I open-label trial

Violaine Harris, PhD, Leslie Blackshear, Gloria Joo, Tamara Vyshkina, Valentina Stefanova, and Saud A. Sadiq, MD Presented at the International Society of Stem Cell Research (ISSCR) annual meeting, held June 22-25, 2016 in San Francisco, CA, USA

Reparative effects of intrathecal MSC-NP cells in patients with multiple sclerosis mediated by trophic and immunomodulatory factors

John Tuddenham, Violaine Harris, PhD, Tamara Vyshkina and Saud Sadiq, MD Presented at the International Society of Stem Cell Research (ISSCR) annual meeting, held June 22-25, 2016 in San Francisco, CA, USA

Long-term clinical stability in a subset of MS patients with minimal therapeutic intervention

Leslie Blackshear, Lena Josephs, and Saud A. Sadiq, MD Presented at the 68th annual meeting of the American Academy of Neurology, held April 15-21, 2016 in Vancouver, BC, Canada.

Read Abstract

Elevated levels of the furan fatty acid metabolite, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) in the serum of multiple sclerosis patients.

Danielle Blemur, Fozia Mir, and Saud Sadiq, MD Presented at the 68th annual meeting of the American Academy of Neurology, held April 15-21, 2016 in Vancouver, BC, Canada.

CSF from progressive-MS patients stimulates microglial activation pathways in vivo and in vitro

Kelsey McDermott, Jeffrey Jian, Jessie Huang, Massimiliano Cristofanilli, Saud Sadiq Presented at the 68th annual meeting of the American Academy of Neurology, held April 15-21, 2016 in Vancouver, BC, Canada.

Fetuin-A, a CSF biomarker of multiple sclerosis disease activity, is upregulated at the blood-CSF barrier

Ruth-Anne Langan, Violaine Harris, Saud Sadiq Presented at the 68th annual meeting of the American Academy of Neurology, held April 15-21, 2016 in Vancouver, BC, Canada.

Thromboxane A2 levels are increased in the CSF of active multiple sclerosis patients

Fozia Mir, Danielle Blemur, Donald Lee, Saud Sadiq Presented at the 68th annual meeting of the American Academy of Neurology, held April 15-21, 2016 in Vancouver, BC, Canada.

Effects of intrathecal MSC-derived neural progenitors (MSC-NP) treatment on biomarker levels in the CSF in patients with progressive multiple sclerosis

John Tuddenham, Violaine Harris, Saud Sadiq Presented at the 68th annual meeting of the American Academy of Neurology, held April 15-21, 2016 in Vancouver, BC, Canada.

Quality control of autologous bone marrow mesenchymal stem cell-derived neural progenitors (MSC-NPs) from patients with multiple sclerosis prior to intrathecal injection

Tamara Vyshkina, Valentina Stefanova, Violaine Harris, Saud Sadiq Presented at the 68th annual meeting of the American Academy of Neurology, held April 15-21, 2016 in Vancouver, BC, Canada.

Pages

Tisch MS Research Center of New York

521 West 57th Street
4th Floor
New York, NY 10019
(646) 557-3900

Privacy Policy

 

Support Tisch MS

Support Tisch MS and our innovative research leading to treatments that improve the lives of patients.